Financial Performance - The company's revenue for Q1 2023 was CNY 850.50 million, a decrease of 3.32% compared to CNY 879.74 million in the same period last year[42]. - Net profit attributable to shareholders was CNY 50.11 million, down 8.77% from CNY 54.92 million year-on-year[42]. - The net cash flow from operating activities was CNY -92.82 million, a significant decline of 282.87% compared to CNY 50.76 million in the previous year[42]. - The net profit for the current period is ¥62,914,975.09, a decrease from ¥66,193,178.35 in the previous period, representing a decline of approximately 4.3%[62]. - The total comprehensive income for the current period is ¥60,401,256.33, down from ¥63,838,402.00 in the previous period, indicating a decrease of about 3.8%[62]. - The basic and diluted earnings per share for the current period are both ¥0.0608, compared to ¥0.0685 in the previous period, reflecting a decline of approximately 10.1%[63]. - The company reported a decrease in sales revenue from cash received for goods sold and services provided, totaling ¥836,066,401.59, down from ¥857,253,309.29 in the previous period[63]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 8,264.59 million, an increase of 1.07% from CNY 8,176.85 million at the end of the previous year[42]. - The company's equity attributable to shareholders was CNY 4,792.97 million, reflecting a 0.93% increase from CNY 4,748.66 million year-on-year[42]. - The total current assets as of March 31, 2023, amounted to CNY 3,230,853,874.60, an increase from CNY 3,192,720,273.08 at the beginning of the year[58]. - The inventory balance increased to CNY 1,196,891,591.38 from CNY 1,078,053,484.87 at the beginning of the year[58]. - The total non-current assets were reported at CNY 2,257,000,000.00 as of March 31, 2023[58]. - The company reported a decrease in long-term equity investments to CNY 79,017,999.22 from CNY 86,616,680.24[58]. - The total liabilities as of March 31, 2023, were CNY 1,500,000,000.00, reflecting a stable financial position[58]. Cash Flow - Cash received from other operating activities increased by 134.53% year-on-year, mainly due to increased deposits received from market expansion in formulations[22]. - Cash received from investment decreased by 78.88% year-on-year, primarily due to a reduction in the maturity of wealth management products[23]. - Cash paid for investments decreased by 61.54% year-on-year, mainly due to a reduction in the purchase of wealth management products[24]. - The net cash flow from operating activities is negative at ¥92,824,560.09, a significant drop from a positive cash flow of ¥50,759,287.12 in the previous period[63]. - Cash inflow from operating activities totaled ¥909,740,103.97, while cash outflow was ¥1,002,564,664.06, resulting in a net cash outflow of ¥92,824,560.09[63]. - The net cash flow from investing activities is negative at ¥148,998,267.71, compared to a negative cash flow of ¥127,163,054.98 in the previous period[64]. - Cash inflow from financing activities is ¥128,300,000.00, while cash outflow is ¥23,562,226.66, leading to a net cash inflow of ¥104,737,773.34[64]. - The ending cash and cash equivalents balance is ¥785,354,287.20, an increase from ¥636,286,441.06 in the previous period[64]. - Cash and cash equivalents decreased to CNY 868,286,731.45 from CNY 1,021,623,576.58 at the beginning of the year[58]. Expenses - Sales expenses increased by 30.48% year-on-year, driven by increased market expenses in the formulation and nuclear medicine business[19]. - Financial expenses increased by 31.07% year-on-year, primarily due to exchange rate impacts resulting in foreign exchange losses[20]. - The company experienced a 90.24% decrease in cash paid for debt repayment, indicating reduced bank loan repayments[50]. - The company reported a 43.72% increase in management expenses, primarily due to costs associated with equity acquisitions[46]. - Other income increased by 299.55%, mainly due to an increase in government subsidies received[47]. Government Support and R&D - Government subsidies recognized in the current period totaled 9,589,346.86 RMB[5]. - The company’s subsidiary received approval for clinical trials of a new drug, indicating ongoing research and development efforts[28]. - The company received approval for a clinical trial of the drug 177 Lu-LNC1004, which will commence in Singapore[57]. Borrowings and Investments - Short-term borrowings increased by 33.70% compared to the beginning of the period, primarily due to increased bank loans[8]. - Trading financial assets increased by 151.92% compared to the beginning of the period, mainly due to the purchase of wealth management products[17].

Financial Performance - Yantai Dongcheng Pharmaceutical Group achieved a revenue of RMB 1.2 billion in 2022, representing a year-on-year growth of 15%[20] - The company reported a net profit of RMB 300 million for the year, an increase of 20% compared to the previous year[20] - The gross margin for 2022 was reported at 45%, with efforts to improve efficiency and reduce costs in the upcoming year[20] - The total revenue for the year 2022 was approximately 2,049,000,000 CNY, a decrease of 16.97% compared to 2021[69] - The main business cost for raw materials was 1,564,775,848 CNY, accounting for 76.54% of the total operating costs[69] - Total sales from the top five customers amounted to ¥1,064,964,438.98, accounting for 29.72% of the annual total sales[73] - Total purchases from the top five suppliers reached ¥788,801,331.34, which is 38.90% of the annual total purchases[73] - Research and development expenses increased by 18.87% to ¥163,520,492.52 compared to the previous year[77] - The number of R&D personnel rose by 69.83% to 394 in 2022, compared to 232 in 2021[81] - Total cash inflow from operating activities was ¥4,406,825,392.95, a 3.47% increase year-on-year[83] - Net cash flow from operating activities was ¥996,537,274.70, reflecting a 5.61% increase from the previous year[83] Market Expansion and Strategy - User data indicated a 25% increase in the number of active customers, reaching 500,000 by the end of 2022[20] - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[20] - The company has set a performance guidance of 10-15% revenue growth for 2023, driven by new product launches and market expansion strategies[20] - The company plans to continue expanding its market presence and investing in research and development to enhance its product offerings[120] Research and Development - The company has invested RMB 50 million in R&D for innovative drug delivery systems, aiming for completion by the end of 2023[20] - New product development includes a low molecular heparin product line, expected to launch in Q3 2023, projected to generate RMB 200 million in revenue[20] - The company is advancing multiple R&D projects aimed at enhancing its product pipeline, including new diagnostic and therapeutic nuclear drugs[78] Acquisitions and Partnerships - The company is exploring potential acquisitions in the biopharmaceutical sector to enhance its product portfolio and market reach[20] - The company has acquired a 70.28% stake in Nanjing Yunmi Enterprise Management Partnership for 35.2625 million RMB and a 99.90% stake in Nanjing Mi'anbei Enterprise Management Partnership for 114.5184 million RMB[50] - The company has purchased clinical approval and research data for the Tau protein PET imaging diagnostic drug for 8 million USD and 14 million RMB, gaining exclusive rights for clinical development, production, and market sales in mainland China[51] - The company has established partnerships with related parties, including the acquisition of shares in related partnerships[52] Financial Management - The company plans to raise a total of up to 349.997 million yuan through a non-public issuance of A shares, with all proceeds intended for replenishing working capital and repaying interest-bearing liabilities[88] - The company has confirmed that there are no overdue amounts in its entrusted financial management, with a total amount of 16,128 thousand yuan and an unexpired balance of 2,732.67 thousand yuan[85] - The company recognized a government subsidy of 200 million yuan, which contributed to an increase in cash flow from operating activities[116] - The company's cash and cash equivalents at year-end amounted to 1,021,623,577, representing 12.49% of total assets, up from 10.80% at the beginning of the year[118] Compliance and Quality Assurance - The company is committed to maintaining compliance with GMP standards across all manufacturing processes to ensure product quality and safety[20] - The company's heparin sodium raw materials passed the official audit by the Korean Ministry of Food and Drug Safety, receiving an audit confirmation letter[91] - The company's technology center has been recognized as a national enterprise technology center in the 29th batch of new recognitions by the National Development and Reform Commission and other authorities[91] Shareholder Information - The company issued 22,381,379 shares on October 20, 2022, increasing total shares from 802,214,326 to 824,595,705[133] - The largest shareholder, Yantai Dongyi Biological Engineering Co., Ltd., holds 15.15% of the shares, totaling 124,888,049 shares[138] - The actual controller of the company is You Shiyi, who holds 51% of Yantai Dongyi Biological Engineering Co., Ltd.[142] Government Subsidies - The company’s subsidiary Dongcheng Nuclear Medicine received a government subsidy of RMB 100 million from the Yantai Municipal Government on April 8, 2022, to support the integration of the nuclear medicine industry[94] - Dongcheng Nuclear Medicine received an additional government subsidy of RMB 90 million on July 19, 2022, from the Yantai Municipal Government[94] - On December 15, 2022, Dongcheng Nuclear Medicine received a further government subsidy of RMB 10 million from the Yantai Municipal Government[94]

为充分尊重投资者、提升交流的针对性，现就公司 2022 年度网上业绩说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 8 日（星期一）17：00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进 入问题征集专题页面。公司将在 2022 年度网上业绩说明会上，对投资者普遍关 注的问题进行回答。 欢迎广大投资者积极参与。 （问题征集专题页面二维码） 证券代码：002675 证券简称：东诚药业 公告编号：2023-024 烟台东诚药业集团股份有限公司 关于举行 2022 年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司（以下简称"公司"）定于 2023 年 5 月 9 日 （星期四）15：00—17:00 举行 2022 年度网上业绩说明会。本次业绩说明会将 采用网络远程的方式举行，投资者可登陆投资者关系互动平台（网址： http://ir.p5w.net/）参与本次业绩说明会。 出席本次年度业绩说明会的人员有：公司总经理罗志刚先生、财务负 ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 编号：2015-001 | --- | --- | --- | --- | |----------------|---------------------------------|--------------------------------------------------------|-------| | | | | | | 投资者关系活动 | | ■特定对象调研 □分析师会议 | | | 类别 | | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 华创证券 张文录 | | | | 人员姓名 | 中信建投证券 高君 | | | | | 国都证券 姚巍 | | | | | 上投摩根基金 方钰涵 | | | | | 交银施罗德基金 张胤 | | | | | 交银施罗德基金 芮晨 | | | | | 博时基金 蔡滨 | | | | | 博时基金 葛晨 | | | | | ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 烟台东诚药业集团股份有限公司投资者关系活动记录表 股份有限公司投资者关系活动记录表 编号：2015-002 | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------|--------------------------------------------------------|-------|-------| | | | | | | | 投资者关系活动 | | ■特定对象调研 □分析师会议 | | | | 类别 | | □媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | 参与单位名称及 | 平安证券 叶寅 | | | | | 人员姓名 | 招商证券 李勇剑 | | | | | | 财通证券 顾明豪 | | | | | | 东兴证券 贾丽杰 | | ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 烟台东诚药业集团股份有限公司投资者关系活动记录表 股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------|--------------------------------------------------------|-------|-------| | | | 编号：2016-002 | | | | 投资者关系活动 | | ■特定对象调研 □分析师会议 | | | | 类别 | | □媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | 参与单位名称及 | 平安证券 叶寅 | | | | | 人员姓名 | 太平资产 许希晨 | | | | | | 万家基金 王霄音 | | | | | | 兴证资管 张昕 | | ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 烟台东诚药业集团股份有限公司投资者关系活动记录表 股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------------|--------------------|-------|--------------------------------------------------------|-------| | | | | 编号：2016-001 | | | 投资者关系活动 | | | ■特定对象调研 □分析师会议 | | | 类别 | | | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 西南证券 周平 | | | | | 人员姓名 | 东北证券 梁静静 | | | | | | IDG 资本 彭世泽 | | | | | | 泰达宏利 周笑雯 | | | | | 时间 | ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 编号：2020-001 | --- | --- | --- | |----------------|--------------------------------|---------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | ■ 其他 （电话会议） | | | 参与单位名称及 | BlackRock | （贝莱德基金） 唐华 | | 人员姓名 | | | | 时间 | 2020 年 3 月 16 | 日 | | 地点 | 烟台经济技术开发区长白山路 | 7 号公司会议室-电话会议 | | 上市公司接待人 | 副总经理兼董事会秘书：刘晓杰 | | | 员姓名 | 证券部：李季 | | | 投资者关系活动 | 了解公司发展情况及经营管理规划 | | | --- | --- | |-------------------- ...